Literature DB >> 21394526

Performance of different data sources in identifying adverse drug events in hospitalized patients.

Marco Egbring1, Elmira Far, Alexander Knuth, Malgorzata Roos, Wilhelm Kirch, Gerd A Kullak-Ublick.   

Abstract

PURPOSE: The incidence of adverse drug events (ADE) is an important parameter in determining the quality of medical care. We identified the probability that a specific data source would identify ADEs in patients on the oncology ward, that could be assigned to one substance.
METHODS: We captured all medical adverse events (AE) from five different data sources. Each AE was determined to be drug-related according to the WHO criteria and classified according to the severity, category, and causality of the ADE.
RESULTS: The study recorded 129 patients with 252 hospitalizations over a 5-month period. A total of 3,341 medical events were captured and resulted in 1,121 ADEs. In 122 patients, at least one ADE (95%) was observed. Only 39 hospitalizations were believed not to have an ADE (15%). No ADE was captured by all data sources. The patient record captured 550, the nursing record 569, the laboratory tests 387, the questionnaire 63, and the event monitoring during grand rounds 141 ADEs. Only the nursing record and the laboratory tests had a significantly different probability of observing indicative ADEs.
CONCLUSION: For all AEs reported in the data sources, physicians and nurses were the best source for ADEs. Data sources differed in identifying indicative ADEs and were influenced by specific patient parameters.

Entities:  

Mesh:

Year:  2011        PMID: 21394526     DOI: 10.1007/s00228-011-1020-9

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  23 in total

Review 1.  Counting the costs of drug-related adverse events.

Authors:  T J White; A Arakelian; J P Rho
Journal:  Pharmacoeconomics       Date:  1999-05       Impact factor: 4.981

2.  Adverse drug reactions in hospitalized patients: A critique of a meta-analysis.

Authors:  M Kvasz; I E Allen; M J Gordon; E Y Ro; R Estok; I Olkin; S D Ross
Journal:  MedGenMed       Date:  2000-04-27

3.  Adverse drug event monitoring at the Food and Drug Administration.

Authors:  Syed Rizwanuddin Ahmad
Journal:  J Gen Intern Med       Date:  2003-01       Impact factor: 5.128

4.  What can hospitalized patients tell us about adverse events? Learning from patient-reported incidents.

Authors:  Saul N Weingart; Odelya Pagovich; Daniel Z Sands; Joseph M Li; Mark D Aronson; Roger B Davis; David W Bates; Russell S Phillips
Journal:  J Gen Intern Med       Date:  2005-09       Impact factor: 5.128

5.  Drug utilization 90%--a simple method for assessing the quality of drug prescribing.

Authors:  U Bergman; C Popa; Y Tomson; B Wettermark; T R Einarson; H Aberg; F Sjöqvist
Journal:  Eur J Clin Pharmacol       Date:  1998-04       Impact factor: 2.953

6.  Costs of medical injuries in Utah and Colorado.

Authors:  E J Thomas; D M Studdert; J P Newhouse; B I Zbar; K M Howard; E J Williams; T A Brennan
Journal:  Inquiry       Date:  1999       Impact factor: 1.730

7.  Risk factors for adverse drug events: a 10-year analysis.

Authors:  R Scott Evans; James F Lloyd; Gregory J Stoddard; Jonathan R Nebeker; Matthew H Samore
Journal:  Ann Pharmacother       Date:  2005-05-16       Impact factor: 3.154

8.  Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study.

Authors:  Ethan Basch; Alexia Iasonos; Tiffani McDonough; Allison Barz; Ann Culkin; Mark G Kris; Howard I Scher; Deborah Schrag
Journal:  Lancet Oncol       Date:  2006-11       Impact factor: 41.316

9.  High prevalence of unknown co-medication in hospitalised patients.

Authors:  Karin Rieger; André Scholer; Isabelle Arnet; Frank T Peters; Hans H Maurer; Ingeborg Walter-Sack; Walter E Haefeli; Meret Martin-Facklam
Journal:  Eur J Clin Pharmacol       Date:  2004-06-10       Impact factor: 2.953

10.  The ten most common adverse drug reactions (ADRs) in oncology patients: do they matter to you?

Authors:  Phyllis M Lau; Kay Stewart; Michael Dooley
Journal:  Support Care Cancer       Date:  2004-09       Impact factor: 3.603

View more
  4 in total

Review 1.  Comparative epidemiology of hospital-acquired adverse drug reactions in adults and children and their impact on cost and hospital stay--a systematic review.

Authors:  Lateef Mohiuddin Khan
Journal:  Eur J Clin Pharmacol       Date:  2013-08-17       Impact factor: 2.953

2.  Recognition of adverse drug events in older hospitalized medical patients.

Authors:  Joanna E Klopotowska; Peter C Wierenga; Susanne M Smorenburg; Clementine C M Stuijt; Lambertus Arisz; Paul F M Kuks; Marcel G W Dijkgraaf; Loraine Lie-A-Huen; Sophia E de Rooij
Journal:  Eur J Clin Pharmacol       Date:  2012-06-07       Impact factor: 2.953

3.  Optimising drug prescribing and dispensing in subjects at risk for drug errors due to renal impairment: improving drug safety in primary healthcare by low eGFR alerts.

Authors:  Hanneke Joosten; Iefke Drion; Kees J Boogerd; Emiel V van der Pijl; Robbert J Slingerland; Joris P J Slaets; Tiele J Jansen; Olof Schwantje; Reinold O B Gans; Henk J G Bilo
Journal:  BMJ Open       Date:  2013-01-24       Impact factor: 2.692

4.  Adverse drug events in older hospitalized patients: results and reliability of a comprehensive and structured identification strategy.

Authors:  Joanna E Klopotowska; Peter C Wierenga; Clementine C M Stuijt; Lambertus Arisz; Marcel G W Dijkgraaf; Paul F M Kuks; Henk Asscheman; Sophia E de Rooij; Loraine Lie-A-Huen; Susanne M Smorenburg
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.